Quality of Life in Patients With Bladder Cancer

NCT00745355 | Active Not Recruiting

• 1 other identifier: 08-076
• Study Type: observational
• Target: 550
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to learn about the quality of life of people living with bladder cancer. We are interested in learning about how the treatments for bladder cancer affect people. We plan to use the findings from this study to help doctors provide better care and information to patients with bladder cancer.

Conditions

Bladder Cancer

Keywords

Quality of Life; Questionnaires; 08-076

Outcome Measures

Primary Outcomes (1)

• Prospectively characterize the impact of radical cystectomy and different urinary diversions on quality of life of bladder cancer patients.

  conclusion of study

Secondary Outcomes (3)

• Compare various standard and idiographic measures of QOL, to determine their relative contributions in accounting for variance in key outcome criteria and prediction of patient QOL at subsequent assessment points.

  conclusion of study

• Examine how patients react to more in-depth probing of the interview associated with idiographic assessment.

  conclusion of study

• Develop a predictive model of QOL after radical cystectomy & urinary diversion using the data from idiographic and standard QOL measures. This model can ultimately be used in office based practice to guide treatment planning with each patient.

  conclusion of study

Study Arms (1)

1

new patients with bladder cancer and/or are scheduled for radical cystectomy and urinary diversion

Behavioral: Quality Of Life questionnaires

Interventions

Quality Of Life questionnaires BEHAVIORAL

All patients who agree to participate will be interviewed using a baseline idiographic quality of life assessment prior to surgery and at approximately 6, 12, 18 and 24 months postoperatively. All patients will also be asked to respond to a questionnaire including all standard measures (closed-ended, multiple choice items) before surgery and at approximately 3, 6, 12, 18 and 24 months post-surgery.

1

Eligibility Criteria

• Age: 18 Years - 99 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All eligible MSKCC patients.

You may qualify if:

• All patients (male and female) who are diagnosed with bladder cancer
• Patients must be scheduled for radical cystectomy and urinary diversion are and/or being evaluated for neo-adjuvant chemotherapy prior to a planned cystectomy.
• Participants must be able to speak English.
• Participants must be able to provide informed consent.
• Participants must be 18 years of age or older to enroll.
• Participant may be eligible for and may receive neoadjuvant or adjuvant chemotherapy.
• Participant may have had intravesicle chemotherapy or immunotherapy (BCG, Interferon).

You may not qualify if:

• Subjects may be excluded from the study based on the following criteria:
• Follow-up care not obtained at MSKCC.
• Metastatic disease at diagnosis.

Sponsors & Collaborators

• Memorial Sloan Kettering Cancer Center: lead
• Albert Einstein College of Medicine: collaborator
• Northwell Health: collaborator
• Lenox Hill Hospital: collaborator
• DeltaQuest Foundation, Inc.: collaborator
• Lahey Hospital & Medical Center: collaborator

Study Sites (1)

Memorial Sloan-Kettering Cancer Center

New York, New York, 10065, United States

Location

Related Links

• Memorial Sloan-Kettering Cancer Center

MeSH Terms

Conditions

Urinary Bladder Neoplasms

Condition Hierarchy (Ancestors)

Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Urinary Bladder Diseases; Urologic Diseases; Male Urogenital Diseases

Study Officials

• Bernard Bochner, MD

  Memorial Sloan Kettering Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 22, 2008
• First Posted: September 3, 2008
• Study Start: August 1, 2008
• Primary Completion (Estimated): August 1, 2026
• Study Completion (Estimated): August 1, 2026
• Last Updated: May 29, 2025

Record last verified: 2025-05

Locations

US (1)